Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in minimally progressive metastatic differentiated thyroid cancer
2020-002468-30Phase 2Completed
- Sponsor
- Ospedali Galliera
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in well-differentiated thyroid cancer (WDTC), sponsored by Ospedali Galliera. Primary endpoint: Progression-free survival. Started Jun 2021; status: completed.
02
Drugs
metformin
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2020-002468-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002468-30.